INmune Bio (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) announced they are working togther to run INmune Bio’s clinical and preclinical data on XPro (XPro1595) through QCi’s Dirac-3S quantum optimization machine, combined with AI and conventional analytics.
XPro is INmune Bio’s investigational dominant-negative TNF drug designed to selectively block soluble TNF (a driver of neuroinflammation) while leaving membrane-bound TNF intact. They have data from preclinical work plus four clinical trials andares advancing it toward a Phase 2b/3 adaptive program in early Alzheimer’s with an inflammation-enriched population. It also holds FDA Fast Track designation.
The Stage 1 work focuses on finding other diseases that share the same biology XPro has already shown activity against, with an emphasis on rare diseases where smaller, faster trials are possible and a pediatric approval could yield a Priority Review Voucher. The companies will also look for biomarkers that predict response. They plan to compare the quantum optimization results against standard statistical and machine-learning methods to test where the quantum approach adds value.
This is QCi’s first commercial customer in the pharmaceutical/biotech sector. The agreement includes options for additional work as INmune Bio’s programs advance.
Most near-term quantum for drug discovery efforts remain early and focused on specific optimization or sampling tasks rather than general advantage. QCi’s Dirac-3S is a room-temperature photonic entropy quantum optimizer, not a general-purpose superconducting or trapped-ion system. Whether it produces actionable new indications or biomarkers beyond what conventional methods already extract from the same datasets will be the practical test of the partnership.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.
